Cerevance Media Center
Current News
December 2, 2016
Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
- Takeda and Lightstone Ventures Participate in Series A Financing
- Former Takeda Cambridge UK employees, CNS programs moved to create turn-key discovery capabilities
News Archive
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
Cerevance chief executive officer, Craig Thompson, will participate in a panel at the Fierce Biotech Summit, taking place in Boston, MA from September 30 – October 1, 2024.
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response.
March 20, 2023
AD/PD™ 2023 International Conference
March 7, 2023
Alzheimer’s Research UK Conference 2023
January 24, 2023
SVB Global Biopharma Conference
Events Archive
October 21, 2024
CVN424, a GPR6 inverse agonist, for Parkinson’s disease and motor fluctuations: a double-blind, randomized, phase 2 trial
April 5, 2024
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
February 26, 2024